Analyst Reco. Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
10.88 ^USD	+3.13%		+10.46%	+15.50%

Nov. 10	Amicus Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 02:45 PM
Nov. 04	Amicus Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025

Analyst Reco.

Sector Update: Health Care Stocks Advance Late Afternoon	Sep. 18	MT
Sector Update: Health Care	Sep. 18	MT
Amicus Therapeutics Shares Rise After Upgrade From Needham	Sep. 18	MT
Needham Upgrades Amicus Therapeutics to Buy From Hold, Price Target is $14	Sep. 18	MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equal Weight, $12 Price Target	Jul. 17	MT
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating	May. 02	MT
Morgan Stanley Downgrades Amicus Therapeutics to Equalweight From Overweight, Cuts Price Target to $12 From $17	Dec. 13	MT
Morgan Stanley Trims Price Target on Amicus Therapeutics to $18 From $19, Keeps Overweight Rating	24-10-11	MT
Jefferies Initiates Amicus Therapeutics at Buy	24-09-06	MT
Wells Fargo Starts Amicus Therapeutics With Overweight Rating, $18 Price Target	24-05-30	MT
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target	24-05-14	MT
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating	24-05-10	MT
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	24-03-18	MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15	23-12-19	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	23-11-09	MT
Morgan Stanley Trims Amicus Therapeutics' Price Target to $14 From $15, Keeps Equalweight Rating	23-10-10	MT
UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating	23-09-29	MT
JPMorgan Raises Price Target on Amicus Therapeutics to $19 From $17, Maintains Overweight Rating	23-09-29	MT
UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating	23-08-09	MT
BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating	23-03-28	MT
Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating	23-03-02	MT
UBS Adjusts Amicus Therapeutics Price Target to $17 From $15, Maintains Buy Rating	23-03-02	MT
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating	23-01-18	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	22-11-08	MT
Berenberg Bank Adjusts Amicus Therapeutics Price Target to $12 From $11 on Improved Confidence in AT-GAA, Maintains Hold Rating	22-11-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Analyst Reco.

Filters